BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma

Department of Pathology, University of Basel, Basel, Switzerland.
Histopathology (Impact Factor: 3.45). 01/2010; 56(2):217-28. DOI: 10.1111/j.1365-2559.2009.03462.x
Source: PubMed


To clarify which immunohistochemical markers could be helpful in distinguishing between classical Hodgkin's lymphoma (cHL) and primary mediastinal B-cell lymphoma (PMBCL) to more narrowly define 'B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and cHL'.
Two hundred and 83 cHLs and 51 PMBCLs were analysed on validated tissue microarray platforms with antibodies to BOB.1, CD15, CD20, CD23, CD30, CD79a, cyclin E, LMP-1, MUM1p, p63 and Oct2. The marker cut-off scores were calculated using receiver-operating characteristic curves. Markers with the highest positive predictive value for cHL were: CD15, cyclin E, LMP-1 (all 100%), MUM1p (93%) and CD30 (83%). High sensitivity was achieved only by CD30 (92%) and cyclin E (79%). Nineteen percent of PMBCLs were also positive for CD30, which led to a lower specificity of CD30 as regards cHL (81%) compared with cyclin E (100%). The antibodies with the highest positive predictive value for PMBCL were: CD23 (98%), p63 (96%), BOB.1 (94%) and CD79a (90%), with high sensitivity for BOB.1 (100%), CD79a (89%) and p63 (82%).
The use of at least three of the most accurate immunohistochemical markers, cyclin E, CD79a and BOB.1, may be helpful in the differential diagnosis of cHL and PMBCL.

9 Reads
  • Source
    • "The neoplastic cells in PMBCL express B-cell markers (CD20, CD79a, CD19, PAX5) and lack expression of HLA class I antigens and surface immunoglobulin (Ig). However, expression of Ig-associated transcription factors BOB1, OCT2, and PU1 is preserved in contrast to cHL [7, 8]. CD30 is expressed in 70% of cases and tumour cells are typically CD23 positive. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The current classification of lymphoid neoplasms is based on clinical information, morphology, immunophenotype, and molecular genetic characteristics. Despite technical and scientific progress, some aggressive B-cell lymphomas with features overlapping between two different types of lymphomas remain difficult to classify. The updated 2008 World Health Organization (WHO) classification of Tumours of the Hematopoietic and Lymphoid Tissues has addressed this problem by creation of two new provisional categories of B-cell lymphomas, unclassifiable; one with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma and the second with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. We review here the diagnostic criteria of these two provisional entities and discuss new scientific findings in light of the 2008 WHO classification.
    Advances in Hematology 04/2012; 2012(5, supplement):460801. DOI:10.1155/2012/460801
  • [Show abstract] [Hide abstract]
    ABSTRACT: Eine krankheitsbedingte oder iatrogene Immunsuppression stellt einen erheblichen Risikofaktor dar, ein malignes Lymphom zu entwickeln. Der medizinische Fortschritt mit Organtransplantationen, erfolgreicher Behandlung von Autoimmunerkrankungen oder einer verbesserten HIV-Therapie bedingt die Zunahme immunsupprimierter Patienten. Verschiedene Formen der Immunsuppression und jeweils typische Lymphomentitäten werden im vorliegenden Artikel erörtert. Einen zweiten Schwerpunkt dieses Updates bilden Grauzonenlymphome zwischen Hodgkin-Lymphom und diffusem großzelligem B-Zell-Lymphom. Diese Kategorie stellt nicht nur ein diagnostisches Problem dar, sondern entspricht vielmehr einem biologischen Kontinuum.
    Der Pathologe 02/2013; 34(1). DOI:10.1007/s00292-012-1706-5 · 0.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionIn this era of precision medicine, targets for new drugs are to be found across the range of tumors. Tissue microarrays are often used for that purpose, and for instance, Fernandez et al. [1] stained 395 lymphomas for Bruton’s tyrosine kinase protein expression showing that many B cell lymphomas, some T cell lymphomas, 14/16 nodular lymphocyte predominant, and 6/27 classic Hodgkin lymphoma (cHL) were positive. However, expression of a protein does not fully correlate with therapy response, so such studies can only serve as an initial screen. A next step is to study the effect of a drug in cell lines, like the work of Choudhary et al. [2], who investigated the effect of a Bcl-2 inhibitor on B cell lymphoma cell lines and also the acquired resistance after treatment. They showed that the B cell lymphoma cells upon treatment with Bcl-2 inhibition increased their expression of MCL-1 and Bcl-x, which resulted in resistance that could be overcome by inhibition of these factors. T ...
    Journal of Hematopathology 06/2010; 3(1):47-58. DOI:10.1007/s12308-010-0060-x
Show more